Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...

Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...